drugset / Trial / NCT07468708
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
Phase 0
Recruiting
10 enrolled
FindCure Biosciences (ZhongShan) Co., Ltd.
First Affiliated Hospital of Jinan University · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the results of ⁶⁸Ga-labeled prostate cancer-targeting tracer imaging to evaluate the dosimetric characteristics and diagnostic efficacy of ⁶⁸Ga-FC516.
Timeline
- Start
- 2026-03-09
- Primary completion
- 2026-07
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ⁶⁸Ga-FC516 | Diagnostic / imaging agent | — | Other |